Clinical Trials Directory

Trials / Completed

CompletedNCT03963739

Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer

Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)

Status
Completed
Phase
Study type
Observational
Enrollment
255 (actual)
Sponsor
Wake Forest University Health Sciences · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

The objective of this study is to examine how adenocarcinoma of the prostate treatment differentially affects African American men's ability to work and to describe and compare changes in work ability (as measured through self-reported global work ability item) reported by African American and white adenocarcinoma of the prostate survivors before treatment and 6 months after treatment completion.

Detailed description

This observational, longitudinal study will recruit approximately 255 patients through the Wake Forest National Cancer Institute Community Oncology Research Program (NCORP) Research Base (WF NCORP RB). The recruitment goal will be to have 160 participants who complete the interviewer-administered Structured Questionnaire at all three time points. All participants will be administered the first Structured Questionnaire prior to a prostatectomy or initiation of radiation therapy to treat adenocarcinoma of the prostate. Participants will also be administered Structured Questionnaires at three and six months after the prostatectomy or completion of radiation therapy. For most patients, the time between study enrollment and completion of participation will be approximately 6 - 10 months. Interviewer-administered Structured Questionnaires will address work ability, job characteristics, presence of symptoms associated with adenocarcinoma of the prostate treatment, and general background information.

Conditions

Interventions

TypeNameDescription
OTHERInterviewUndergo interview
OTHERQuestionnaire AdministrationAncillary studies

Timeline

Start date
2019-07-19
Primary completion
2025-03-25
Completion
2025-03-25
First posted
2019-05-28
Last updated
2025-07-16

Locations

326 sites across 2 countries: United States, Guam

Source: ClinicalTrials.gov record NCT03963739. Inclusion in this directory is not an endorsement.